Ask a Question

User nancyfall94

Member for: 2 years (since Jan 26, 2023)
Type: Registered user
Full name:
Location:
Website:
About: Real-world efficacy and protection involving anlotinib since third- or even further-line therapy in refractory small mobile cancer of the lung.

Activity by nancyfall94

Score: 100 points (ranked #10)
Questions: 0
Answers: 0
Comments: 0
Voted on: 0 questions, 0 answers
Gave out: 0 up votes, 0 down votes
Received: 0 up votes, 0 down votes

Wall for nancyfall94

Please log in or register to post on this wall.
Snow Theme by Q2A Market
Powered by Question2Answer
...